Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THVโs single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Companyโs ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
์ข
๋ชฉ ์ฝ๋ AVR
ํ์ฌ ์ด๋ฆAnteris Technologies Global Corp
์์ฅ์ผDec 13, 2024
CEOPaterson (Wayne G)
์ง์ ์136
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 13
์ฃผ์860 Blue Gentian Road
๋์EAGAN
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ55121
์ ํ16514930606
์น์ฌ์ดํธhttps://anteristech.com/
์ข
๋ชฉ ์ฝ๋ AVR
์์ฅ์ผDec 13, 2024
CEOPaterson (Wayne G)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์